Navigation Links
Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Date:5/3/2012

ure to dabigatran. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to increase exposure of dabigatran compared to either factor alone.

  • For patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when dronedarone or systemic ketoconazole is coadministered with PRADAXA.
  • For patients with severe renal impairment (CrCl 15-30 mL/min), avoid concomitant use of PRADAXA and P-gp inhibitors.

ADVERSE REACTIONS

In the pivotal trial comparing PRADAXA to warfarin, the most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal (GI) events. PRADAXA 150 mg resulted in a higher rate of major GI bleeds and any GI bleeds compared to warfarin. In patients ≥75 years of age, the risk of major bleeding may be greater with PRADAXA than with warfarin. Patients on PRADAXA 150 mg had an increased incidence of GI adverse reactions. These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

OTHER MEASURES EVALUATED

The risk of myocardial infarction was numerically greater in patients who received PRADAXA 150 mg than in those who received warfarin.

For full PRADAXA prescribing information, please visit www.pradaxa.com or contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257.

About the Boehringer Ingelheim Cares Foundation Patient Assistance Programs

For more than 125 years, Boehringer Ingelheim has been focused on improving the lives of patients
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... SAINT PAUL, Minn. , Aug. 1, 2014 ... leading global medical technologies company, announced today that ... a privately held manufacturer of cardiorespiratory diagnostic products ... MediSoft has served the European cardiorespiratory ... company, generated 2013 revenues of approximately €4.7 million ...
(Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... 01, 2014 As AndroGel lawsuits and ... Ronald E. Johnson, Jr. has been appointed as co-lead ... other testosterone medications. Since the Fall of 2013, Ron ... worked diligently to investigate and prosecute the claims of ... blood clots as a result of taking testosterone. As ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
(Date:8/1/2014)... 01, 2014 The "Antimicrobial Coatings ... as Zinc Oxide, Titanium Dioxide, and Zinc Omadine), ... Construction, Food & Beverages, Textiles, and others), & ... Global Trends and Forecasts to 2018" analyzes the ... opportunities, and trends in the diverse geographical regions. ...
(Date:8/1/2014)... According to new market research report "Automotive Exhaust ... & ROW), by Vehicle Type (Passenger Cars, LCVs, ... by After-Treatment Device (DPF, DOC, SCR, TWC, & ... defines and segments the global automotive exhaust systems ... all the regions, and estimates their exhaust systems ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Inc. (AIS), publisher of industry-leading newsletters Health Plan,Week, ... pleased to announce,publication of "Managed Medicare and Medicaid ... and almost 30 million Medicaid recipients,enrolled in managed ... other,companies with a stake in this market place ...
... 21 Mylan Inc. (NYSE: MYL ),today ... approval,from the U.S. Food and Drug Administration (FDA) ... Extended-release Tablets USP, 2.5,mg, 5 mg and 10 ... generic version of,AstraZeneca Pharmaceutical,s Plendil(R) Extended-release tablets, which ...
... upcoming Public Meeting on April 22, 2008, the Centers ... input for the establishment of a Healthcare Common Procedure ... II of the HCPCS is a standardized coding system ... not included in the Current Procedural Terminology (CPT) coding ...
... -- China Medicine,Corporation (OTC Bulletin Board: CHME; ... and developer of ethical and over-the-counter drugs,traditional ... devices, and medical formulations in the PRC, ... the Guangzhou Technology Bureau to represent,Guangzhou city,s ...
... Research Group survey finds that approximately 45% of physicians, intend to ... ... years, WALTHAM, Mass., April ... at the American Academy of,Orthopedic Surgeons, annual meeting in San Francisco, CA, ...
... BRIGHTON, England, April 21 Futuremedia,Learning, a leading ... Bulletin Board: FMDAY), has launched Performance Zone, a ... health,and care organisation., The launch took place ... the,UK, with Futuremedia Learning staff on-site offering support ...
Cached Medicine News:Health News:New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits 2Health News:Medicare to consider public opinion about medical maggots 2Health News:Medicare to consider public opinion about medical maggots 3Health News:China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention 2Health News:China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention 3Health News:Physicians Anticipate Changes in Their Usage of Hip Implants 2Health News:Futuremedia Learning Launches Next Generation Learning Portal for Bupa 2
... for Bi-Plane Electrophysiology imaging have become more ... time and reduce radiation exposure to both ... deciding between Single and Bi-Plane systems. ... its leadership position in price/value relationship, four ...
... is now known as Centricity® Physician Office ... - PM is designed to fit your ... easily adaptable solution as individual as your ... every specialty and size - have switched ...
... Care Electronic Medical Record portion of PrimeSuite™. ... process and electronic patient record solution within ... both mobile and secure. Using a variety ... technology with a stylus device, physicians can ...
... Practice Partner Patient Records provides a ... both office and clinical efficiency, while ... Patient Records allows practices to replace ... feature set utilized nationwide by over ...
Medicine Products: